223 related articles for article (PubMed ID: 37858626)
1. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation.
Lu P; Leslie F; Wang H; Sodhi A; Choi CY; Pekosz A; Cui H; Jia H
J Control Release; 2023 Dec; 364():1-11. PubMed ID: 37858626
[TBL] [Abstract][Full Text] [Related]
2. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Sharma RK; Stevens BR; Obukhov AG; Grant MB; Oudit GY; Li Q; Richards EM; Pepine CJ; Raizada MK
Hypertension; 2020 Sep; 76(3):651-661. PubMed ID: 32783758
[TBL] [Abstract][Full Text] [Related]
3. A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to
Sodhi CP; Nguyen J; Yamaguchi Y; Werts AD; Lu P; Ladd MR; Fulton WB; Kovler ML; Wang S; Prindle T; Zhang Y; Lazartigues ED; Holtzman MJ; Alcorn JF; Hackam DJ; Jia H
J Immunol; 2019 Dec; 203(11):3000-3012. PubMed ID: 31645418
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg
Sodhi CP; Wohlford-Lenane C; Yamaguchi Y; Prindle T; Fulton WB; Wang S; McCray PB; Chappell M; Hackam DJ; Jia H
Am J Physiol Lung Cell Mol Physiol; 2018 Jan; 314(1):L17-L31. PubMed ID: 28935640
[TBL] [Abstract][Full Text] [Related]
5. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
Ni W; Yang X; Yang D; Bao J; Li R; Xiao Y; Hou C; Wang H; Liu J; Yang D; Xu Y; Cao Z; Gao Z
Crit Care; 2020 Jul; 24(1):422. PubMed ID: 32660650
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
7. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D
Elife; 2020 Jul; 9():. PubMed ID: 32633718
[TBL] [Abstract][Full Text] [Related]
10. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice.
Imai Y; Kuba K; Penninger JM
Exp Physiol; 2008 May; 93(5):543-8. PubMed ID: 18448662
[TBL] [Abstract][Full Text] [Related]
11. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
Sinha S; Cheng K; Schäffer AA; Aldape K; Schiff E; Ruppin E
Mol Syst Biol; 2020 Jul; 16(7):e9628. PubMed ID: 32729248
[TBL] [Abstract][Full Text] [Related]
15. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
16. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
17. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
[TBL] [Abstract][Full Text] [Related]
20. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
